M. Singer and M. G. Mutch, Anal melanoma, Clin Colon Rectal Surg, vol.19, issue.2, pp.78-87, 2006.

T. R. Coté and L. H. Sobin, Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin, Melanoma Res, vol.19, issue.1, pp.58-60, 2009.

B. K. Ragnarsson-olding, P. J. Nilsson, L. B. Olding, and B. R. Nilsson, Primary anorectal malignant melanomas within a population-based national patient series in Sweden during 40 years, Acta Oncol, vol.48, issue.1, pp.125-156, 2009.

M. S. Brady, J. P. Kavolius, and S. H. Quan, Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center, Dis Colon Rectum, vol.38, issue.2, pp.146-51, 1995.

C. Yen, H. Chen, S. Chiang, C. Yeh, J. Chen et al., Anorectal melanoma: review of 22 consecutive cases, Hepatogastroenterology, vol.60, issue.121, pp.89-93, 2013.

P. Kelly, G. K. Zagars, J. N. Cormier, M. I. Ross, and B. A. Guadagnolo, Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience, Cancer, vol.117, issue.20, pp.4747-55, 2011.

K. W. Kim, H. K. Ha, A. Y. Kim, T. K. Kim, J. Kim et al., Primary malignant melanoma of the rectum: CT findings in eight patients, Radiology, vol.232, issue.1, pp.181-187, 2004.

J. Thierauf, J. A. Veit, J. Hess, N. Treiber, C. Lisson et al., Checkpoint inhibition for advanced mucosal melanoma, Eur J Dermatol, vol.27, issue.2, pp.160-165, 2017.

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, vol.372, issue.1, pp.30-39, 2015.

A. N. Shoushtari, R. R. Munhoz, D. Kuk, P. A. Ott, D. B. Johnson et al., The efficacy of anti-PD-1 agents in acral and mucosal melanoma, Cancer, vol.122, issue.21, pp.3354-62, 2016.

E. Saâda-bouzid, C. Defaucheux, A. Karabajakian, V. P. Coloma, V. Servois et al., Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.28, issue.7, pp.1605-1616, 2017.

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin Cancer Res, vol.23, issue.8, pp.1920-1928, 2017.

H. Ledford, Promising cancer drugs may speed tumours in some patients, Nature, vol.544, issue.7648, pp.13-17, 2017.

T. Landre, F. Karaoud, and C. Taleb,

, Soins Gerontol, vol.22, issue.127, pp.30-33, 2017.

D. I. Gabrilovich, Myeloid-derived suppressor cells, Cancer Immunol Res, vol.5, issue.1, pp.3-8, 2017.

A. C. Huang, M. A. Postow, R. J. Orlowski, R. Mick, B. Bengsch et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, issue.7652, pp.60-65, 2017.

S. Kato and R. Kurzrock, Genomics of immunotherapy-associated hyperprogressorsresponse, Clin Cancer Res, vol.23, issue.20, p.6376, 2017.

C. Krieg, M. Nowicka, S. Guglietta, S. Schindler, F. J. Hartmann et al., High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy, Nat Med, vol.24, issue.2, pp.144-53, 2018.

C. V. Jakubzick, G. J. Randolph, and P. M. Henson, Monocyte differentiation and antigen-presenting functions, Nat Rev Immunol, vol.17, issue.6, pp.349-62, 2017.

J. Erickson, P. Gilchuk, A. Hastings, S. Tollefson, M. Johnson et al., Viral acute lower respiratory infections impair CD8+ T cells through PD-1, J Clin Invest, vol.122, issue.8, pp.2967-82, 2012.